Clinical Trials Browser

Phase 3 × Recruiting × Gynecologic × Clear all

NCT05256225 2026-03-18

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT07061977 2026-03-18

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Phase 3 Recruiting

Locally Advanced Cervical Adenocarcinoma

NCT06072781 2026-03-17

RAMP 301

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

NCT07214779 2026-03-16

MAESTRA 2

Phase 3 Recruiting

Ovarian Neoplasms

NCT06459180 2026-03-13

TroFuse-020

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT06824467 2026-03-13

TroFuse-022

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06952504 2026-03-13

TroFuse-033

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07216703 2026-03-13

TroFuse-036

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT07318558 2026-03-13

TroFuse-021

Phase 3 Recruiting

Ovarian Neoplasms

NCT06989112 2026-03-12

DE-01

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07198074 2026-03-10

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Recruiting

Endometrial Neoplasms

NCT04575935 2026-03-05

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06819007 2026-03-05

DO-01

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT07044336 2026-03-05

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Phase 3 Recruiting

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT07166094 2026-03-03

RAINFOL-03

Phase 3 Recruiting

Recurrence, Endometrial Neoplasms

NCT07225270 2026-03-03

RAINFOL-04

Phase 3 Recruiting

Ovarian Neoplasms

NCT06915025 2026-02-27

OVATION-3

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05581121 2026-02-25

PAROLA

Phase 3 Recruiting

Adenocarcinoma, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT05445778 2026-02-23

GLORIOSA

Phase 3 Recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06651697 2026-02-17

BEFORE

Phase 3 Recruiting

Pelvic Neoplasms

NCT07022483 2026-02-04

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms

NCT06340568 2026-02-02

Fern-EC-01

Phase 3 Recruiting

Endometrial Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

Phase 3 Recruiting

Endometrial Neoplasms

NCT07218809 2026-01-16

TREVI-OC-01

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial

NCT06580314 2026-01-14

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT05659381 2025-12-24

HOTT

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06963268 2025-12-19

SENTOV II

Phase 3 Recruiting

Ovarian Neoplasms

NCT06855069 2025-12-17

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT03422198 2025-12-12

SAVE

Phase 3 Recruiting

188 enrolled 15 charts

GynecologicSarcoma

Endometrial Clear Cell Adenocarcinoma

NCT07168200 2025-11-17

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Phase 3 Recruiting

Advanced Cervical Cancer

NCT06915727 2025-10-08

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

Phase 3 Recruiting

GynecologicHead & Neck

Head and Neck Neoplasms, Pelvic Neoplasms

NCT06817161 2025-10-07

ESTANVO

Phase 3 Recruiting

Digestive System Diseases, Ovarian Neoplasms

NCT05804370 2025-10-01

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Phase 3 Recruiting

Ovarian Neoplasms

NCT04111978 2025-09-29

MATAO

Phase 3 Recruiting

Fallopian Tube Neoplasms, Peritoneal Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05078047 2025-06-05

MOIO

Phase 3 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Esophageal Squamous Cell Carcinoma, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04878094 2025-05-30

A Study of Intra-operative Imaging in Women With Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT06156514 2025-05-28

MICHELE

Phase 3 Recruiting

Locally Advanced Cervical Cancer

NCT06459687 2025-05-14

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT06834672 2025-04-13

Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Recruiting

Fallopian Tube Neoplasms

NCT06641635 2025-03-18

Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT05601700 2025-01-27

LEPRE

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial

NCT06584032 2025-01-07

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Phase 3 Recruiting

Endometrial Neoplasms

NCT06692166 2024-11-22

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

Phase 3 Recruiting

Uterine Cervical Diseases, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Uterine Diseases, Uterine Neoplasms

NCT04921527 2024-10-18

CHIPRO

Phase 3 Recruiting

Ovarian Neoplasms, Recurrence

NCT06394492 2024-08-09

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT05764044 2024-07-30

AddChemo

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Recruiting

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT03785288 2024-05-20

Vaginal Cuff Brachytherapy Fractionation Study

Phase 3 Recruiting

Endometrial Neoplasms